FGC
CORT icon

Financial Gravity Companies’s Corcept Therapeutics CORT Stock Holding History

Financial Gravity Companies’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$31K Buy
+3,059
New +$40.4K 0.03% 432

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Financial Gravity Companies's CORT Position: Q4 2018 in Review

Financial Gravity Companies opened a new position in Corcept Therapeutics (CORT) in Q4 2018: 3,059 shares worth $31K. The stake represents 0.03% of the portfolio and ranks #432 among its holdings.

222 funds tracked by Wall St. Rank hold CORT as of Q4 2018.

  • Financial Gravity Companies held 3,059 shares of Corcept Therapeutics worth $31K as of Q4 2018.
  • Corcept Therapeutics was a new Financial Gravity Companies position in Q4 2018.
  • Corcept Therapeutics made up 0.03% of Financial Gravity Companies's portfolio in Q4 2018, its #432 holding.
  • 222 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2018.

Based on Financial Gravity Companies's 13F filing for Q4 2018, filed 4 Feb 2019.